Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial
    Journal Article

    Krug, L. M.; Crapanzano, J. P.; Azzoli, C. G.; Miller, V. A.; Rizvi, N.; Gomez, J.; Kris, M. G.; Pizzo, B.; Tyson, L.; Dunne, M.; more...
    Cancer (2005)

    Fulltext@MSK | Save
  • Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study
    Meeting Abstract

    Milton, D. T.; Miller, V. A.; Azzoli, C. G.; Dunne, M.; Gomez, J. E.; Heelan, R.; Krug, L. M.; Ramies, D.; Rizvi, N. A.; Kris, M. G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Pharmacokinetic interaction study evaluating the effect of BMS-275291 on the pharmacokinetics of paclitaxel and carboplatin in patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Malik, S. M.; Hwang, J. J.; Belani, C. P.; Galbraith, S.; Bai, S.; Rizvi, N. A.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial
    Meeting Abstract

    Krug, L. M.; Crapanzano, J. P.; Miller, V. A.; Azzoli, C. G.; Rizvi, N.; Gomez, J.; Pizzo, B.; Tyson, L.; Dunne, M.; Kris, M. G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Journal Article

    Miller, V. A.; Kris, M. G.; Shah, N.; Patel, J.; Azzoli, C.; Gomez, J.; Krug, L. M.; Pao, W.; Rizvi, N.; Pizzo, B.; more...
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
    Journal Article

    Rocha Lima, C. M. S.; Rizvi, N. A.; Zhang, C.; Herndon, J. E.; Crawford, J.; Govindan, R.; King, G. W.; Green, M. R.
    Annals of Oncology (2004)

    Fulltext@MSK | Save